Unknown

Dataset Information

0

Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer.


ABSTRACT: NOV-002 (a formulation of disodium glutathione disulfide) modulates signaling pathways involved in tumor cell proliferation and metastasis and enhances anti-tumor immune responsiveness in tumor models. The addition of NOV-002 to chemotherapy has been shown to increase anti-tumor efficacy in animal models and some early phase oncology trials. We evaluated the clinical effects of NOV-002 in primary breast cancer, whether adding NOV-002 to standard preoperative chemotherapy increased pathologic complete response rates (pCR) at surgery, and determined whether NOV-002 mitigated hematologic toxicities of chemotherapy and whether levels of myeloid derived suppressor cells (MDSC) were predictive of response. Forty-one women with newly diagnosed stages II-IIIc HER-2 negative breast cancer received doxorubicin-cyclophosphamide followed by docetaxel (AC ? T) every 3 weeks and concurrent daily NOV-002 injections. The trial was powered to detect a doubling of pCR rate from 16 to 32% with NOV-002 plus AC ? T (? = 0.05, ? = 80%). Weekly complete blood counts were obtained as well as circulating MDSC levels on day 1 of each cycle were quantified. Of 39 patients with 40 evaluable tumors, 15 achieved a pCR (38%), meeting the primary endpoint of the trial. Concurrent NOV-002 resulted in pCR rates for AC ? T chemotherapy higher than previously reported. Patients with lower levels of circulating MDSCs at baseline and on the last cycle of chemotherapy had significantly higher probability of a pCR (P = 0.02). Further evaluation of NOV-002 in a randomized study is warranted.

SUBMITTER: Montero AJ 

PROVIDER: S-EPMC3697917 | biostudies-literature | 2012 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer.

Montero A J AJ   Diaz-Montero C M CM   Deutsch Y E YE   Hurley J J   Koniaris L G LG   Rumboldt T T   Yasir S S   Jorda M M   Garret-Mayer E E   Avisar E E   Slingerland J J   Silva O O   Welsh C C   Schuhwerk K K   Seo P P   Pegram M D MD   Glück S S  

Breast cancer research and treatment 20111203 1


NOV-002 (a formulation of disodium glutathione disulfide) modulates signaling pathways involved in tumor cell proliferation and metastasis and enhances anti-tumor immune responsiveness in tumor models. The addition of NOV-002 to chemotherapy has been shown to increase anti-tumor efficacy in animal models and some early phase oncology trials. We evaluated the clinical effects of NOV-002 in primary breast cancer, whether adding NOV-002 to standard preoperative chemotherapy increased pathologic com  ...[more]

Similar Datasets

| S-EPMC2785076 | biostudies-literature
| S-ECPF-GEOD-41998 | biostudies-other
2013-01-01 | GSE41998 | GEO
2013-01-01 | E-GEOD-41998 | biostudies-arrayexpress
| S-EPMC5080811 | biostudies-literature
| S-EPMC3720631 | biostudies-literature
| S-EPMC4029391 | biostudies-literature
| S-EPMC4822110 | biostudies-literature
| S-EPMC5330708 | biostudies-literature
| S-EPMC3341494 | biostudies-literature